Evaluation of bupivacaine-induced muscle regeneration in the treatment of ptosis in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome
- 1 November 1999
- journal article
- research article
- Published by Springer Nature in Eye
- Vol. 13 (6) , 769-772
- https://doi.org/10.1038/eye.1999.225
Abstract
Purpose Ptosis is common in patients with mitochondrial disease. Whilst surgical shortening of the levator muscle can mechanically elevate the lid, this procedure does not restore normal movement and leaves patients at risk of corneal exposure due to concomitant ophthalmoparesis. Recent studies have shown that bupivacaine-induced muscle regeneration is capable of reversing the molecular genetic and biochemical defect in patients with mitochondrial myopathies. This study was undertaken to assess the potential of this approach in restoring levator muscle function in patients with mitochondrial disease and ptosis. Methods The levator muscle of one eye in five patients with molecularly genetically confirmed mitochondrial DNA disease and ptosis was directly injected with 3 ml of bupivacaine hydrochloride (0.75%). Levator function was compared before and 3 months after the injection. Results No objective clinical improvement in levator function was detected following bupivacaine administration. Discussion The lack of functional recovery seen in our patients is most likely to result from a failure of bupivacaine to induce sufficient regeneration necessary to improve levator muscle function. This result indicates that consideration now needs to be given to the use of alternative and more potent myotoxic agents capable of inducing a more widespread regenerative response from the endogenous muscle satellite cells which contain low or undetectable amounts of mutant mitochondrial DNA.Keywords
This publication has 16 references indexed in Scilit:
- Bioenergetic consequences of accumulating the common 4977‐bp mitochondrial DNA deletionEuropean Journal of Biochemistry, 1998
- Clinical features, investigation, and management of patients with defects of mitochondrial DNAJournal of Neurology, Neurosurgery & Psychiatry, 1997
- Reversal of a mitochondrial DNA defect in human skeletal muscleNature Genetics, 1997
- A novel heteroplasmic tRNAleu(CUN) mtDNA point mutation in a sporadic patient with mitochondrial encephalomyopathy segregates rapidly in skeletal muscle and suggests an approach to therapyHuman Molecular Genetics, 1996
- Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathyHuman Molecular Genetics, 1994
- MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts.Proceedings of the National Academy of Sciences, 1992
- Mitochondrial Genetics: A Paradigm for Aging and Degenerative Diseases?Science, 1992
- Extraocular Muscle Regeneration in PrimatesOphthalmology, 1992
- Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction.Proceedings of the National Academy of Sciences, 1991
- Heteroplasmy of mitochondrial genomes in clonal cultures from patients with Kearns-Sayre syndromeBiochemical and Biophysical Research Communications, 1989